Pluristem Therapeutics Inc. is a company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first product, PLX-I, is directed at resolving the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (UCB).

Contact Information

MATAM Advanced Technology Park
Building No 20
Haifa, 31905

tel: 972 4 850 1080
fax: 972 4 850 1085


Investor Relations



Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $12.1M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.